“Cell-addictive” dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathway

α-synclein (αS) aggregation is a representative molecular feature of the pathogenesis of Parkinson's disease (PD). Epigallocatechin gallate (EGCG) can prevent αS aggregation in vitro. However, the in vivo effects of PD treatment are poor due to the obstacles of EGCG accumulation in dopaminergic...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, YanHui, Chen, ZiXuan, Lu, ZhiGuo, Yang, QingHu, Liu, LinYing, Jiang, ZhaoTan, Zhang, LiQun, Zhang, Xin, Qing, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276100/
https://www.ncbi.nlm.nih.gov/pubmed/30555558
http://dx.doi.org/10.7150/thno.28295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276100/
https://www.ncbi.nlm.nih.gov/pubmed/30555558
http://dx.doi.org/10.7150/thno.28295

Ejemplares similares